trial

Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

NCTId NCT00856583
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 9,809 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2008-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
9,809 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2002-07
Primary completion
2008-02
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
SertindoleRisperidone

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

0 total

Linked catalysts

1
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use — primary completion2008-02

Facts & assertions

4 sourced
Enrollment
9,809
Phase
PHASE3
Primary Completion Date
2008-02
Status
COMPLETED
relationships
The graph out of here
drug
Sertindole
drug
Risperidone
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication